http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103330709-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_52161dbeae9abc88ea5e7a6b9d856732 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4045 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4178 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-08 |
| filingDate | 2013-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e244b0f40c4f7e6d47fd0492455dcfa http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5a88f4edaa9b42c92ea9b76f5e9f8e60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bf8e9af8bc064f49d9a67f05179ee393 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_afdd83727374211db0a2b5700635fe25 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d7de0ea56a7d0de30f8a1e62f689174f |
| publicationDate | 2013-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103330709-A |
| titleOfInvention | Ondansetron composition for injection |
| abstract | The invention provides an andansetron composition for injection, relating to the technical field of drugs and drug preparation. The main drugs of the andansetron composition include andansetron and melatonin, wherein the melatonin comprises a quick-release part and a cyclodextrin encapsulated slow-release part. The andansetron composition for injection, provided by the invention, has the advantages that the treatment effect of the andansetron is improved, the instability of the MT (melatonin), caused by the oral absorption of the MT and the fast distribution and elimination of the MT are avoided, the first-pass effect of the MT is reduced, the dosage of the andansetron is reduced, the quick-release and slow-release combined drug administration design is in line with the physiological secretion characteristic of the MT, the problem of short half-life period of the MT is solved, the biological availability of the product is improved, the melatonin has a synergistic effect on the andansetron for CINV (Chemotherapy Induced Nausea And Vomiting) treatment, after the melatonin and the andansetron are combined, the CINV can be treated, the treatment effect of the andansetron on the CINV are improved, the treatment course is shortened, the usage and the side effect of the andansetron are reduced, and the immunity of human bodies can be improved; and a certain concentration of melatonin maintained in the blood of the human body can be used for effectively reducing the stress reaction of organisms and is facilitated to the treatment of the CINV. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109464404-A |
| priorityDate | 2013-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 38.